[go: up one dir, main page]

WO2006117165A3 - Means and methods for the treatment of head injuries and stroke - Google Patents

Means and methods for the treatment of head injuries and stroke Download PDF

Info

Publication number
WO2006117165A3
WO2006117165A3 PCT/EP2006/004022 EP2006004022W WO2006117165A3 WO 2006117165 A3 WO2006117165 A3 WO 2006117165A3 EP 2006004022 W EP2006004022 W EP 2006004022W WO 2006117165 A3 WO2006117165 A3 WO 2006117165A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
stroke
methods
head injuries
saha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/004022
Other languages
French (fr)
Other versions
WO2006117165A2 (en
Inventor
Ingmar Bluemcke
Eric Hahnen
Florian Siebzehnruebl
Rolf Buslei
Ilker Yasin Eyuepoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Friedrich Alexander Universitaet Erlangen Nuernberg
Original Assignee
Friedrich Alexander Universitaet Erlangen Nuernberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friedrich Alexander Universitaet Erlangen Nuernberg filed Critical Friedrich Alexander Universitaet Erlangen Nuernberg
Publication of WO2006117165A2 publication Critical patent/WO2006117165A2/en
Publication of WO2006117165A3 publication Critical patent/WO2006117165A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of HDAC inhibitors for the preparation of a pharmaceutical composition for the amelioration, treatment or prevention of malignancies related to ischemic events or brain damage, whereby said HDAC inhibitor is selected from the group consisting of SAHA, M344, MS-275, CBHA and SBHA and whereby said HDAC inhibitor is most preferably SAHA.
PCT/EP2006/004022 2005-05-02 2006-04-28 Means and methods for the treatment of head injuries and stroke Ceased WO2006117165A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPEP05009614 2005-05-02
EP05009614 2005-05-02

Publications (2)

Publication Number Publication Date
WO2006117165A2 WO2006117165A2 (en) 2006-11-09
WO2006117165A3 true WO2006117165A3 (en) 2007-04-26

Family

ID=36954780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004022 Ceased WO2006117165A2 (en) 2005-05-02 2006-04-28 Means and methods for the treatment of head injuries and stroke

Country Status (1)

Country Link
WO (1) WO2006117165A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090325862A1 (en) * 2006-05-04 2009-12-31 Christian Steinkuhler Histone Deacetylase Inhibitors for the Treatment of Neurodegeneration
WO2008126932A2 (en) * 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
US9435813B2 (en) 2010-05-11 2016-09-06 The General Hospital Corporation Biomarkers of hemorrhagic shock
EP2683371B1 (en) * 2011-03-09 2020-10-21 Cereno Scientific AB Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
MX355015B (en) * 2011-09-15 2018-04-02 Univ Taipei Medical Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury.
US20160008336A1 (en) * 2013-03-05 2016-01-14 Lixte Biotechnology, Inc. Hdac inhibitors for the treatment of traumatic brain injury
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
WO2017175013A1 (en) 2016-04-08 2017-10-12 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLANCHARD F ET AL: "Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 10, no. 3, 1 February 2005 (2005-02-01), pages 197 - 204, XP004748155, ISSN: 1359-6446 *
CHUANG D-M: "Lithium protection from glutamate excitotoxicity: therapeutic implications", CLINICAL NEUROSCIENCE RESEARCH, ELSEVIER, LONDON, GB, vol. 4, no. 3-4, December 2004 (2004-12-01), pages 243 - 252, XP004732774, ISSN: 1566-2772 *
EYAL S ET AL: "The activity of antiepileptic drugs as histone deacetylase inhibitors", EPILEPSIA 2004 UNITED STATES, vol. 45, no. 7, 2004, pages 737 - 744, XP009048454, ISSN: 0013-9580 *
FARACO G ET AL: "Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain", MOLECULAR PHARMACOLOGY 2006 UNITED STATES, vol. 70, no. 6, 2006, pages 1876 - 1884, XP009077326, ISSN: 0026-895X 1521-0111 *
GLASER K B ET AL: "Differential protein acetylation induced by novel histone deacetylase inhibitors.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 17 DEC 2004, vol. 325, no. 3, 17 December 2004 (2004-12-17), pages 683 - 690, XP004635478, ISSN: 0006-291X *
JEONG M R ET AL: "Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 542, no. 1-3, 8 May 2003 (2003-05-08), pages 74 - 78, XP004422726, ISSN: 0014-5793 *
SUURONEN T ET AL: "Regulation of microglial inflammatory response by histone deacetylase inhibitors", JOURNAL OF NEUROCHEMISTRY 2003 UNITED KINGDOM, vol. 87, no. 2, 2003, pages 407 - 416, XP002415488, ISSN: 0022-3042 *

Also Published As

Publication number Publication date
WO2006117165A2 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2010032875A3 (en) Heterocyclic carboxamide compounds
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2011091213A3 (en) Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
CL2007001882A1 (en) COMPOUNDS DERIVED FROM IMIDAZOPIRIMIDINE; PROCESS TO PREPARE THE COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE PREVENTION AND / OR TREATMENT OF COGNITIVE DISORDERS.
WO2008088030A1 (en) Composition for prevention or treatment of disease associated with thrombus or embolus
WO2007077186A8 (en) Pdf inhibitors
EP2607348A3 (en) Plasminogen Activator Inhibitor-1 Inhibitor
CL2007001881A1 (en) COMPOUNDS DERIVED FROM IMIDAZOPIRIMIDINE; PROCESS TO PREPARE THE COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE PREVENTION AND / OR TREATMENT OF COGNITIVE DISORDERS.
WO2008073138A3 (en) Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
CL2007000918A1 (en) COMPOUNDS DERIVED FROM ENFUMAFUNGINA, INHIBITORS OF (1,3) -BETA-D-GLUCANOSINTETASE; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT A FUNGICAL INFECTION.
González-Muñoz et al. N-acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer’s disease
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
WO2006117165A3 (en) Means and methods for the treatment of head injuries and stroke
WO2008104852A3 (en) Pharmaceutical compositions comprising adsorbate of fenofibrate
WO2011011420A3 (en) 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
MX372773B (en) (2s, 4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
WO2008055022A3 (en) Carbamate compounds for use in treating depression
DK1954251T3 (en) Long-release release composition having iron salt as active ingredient, process for its preparation and use thereof
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
BRPI0516128A (en) use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
WO2004060369A8 (en) Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
WO2009148600A8 (en) Deuterated lysine-based compounds
WO2007095611A3 (en) Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06724646

Country of ref document: EP

Kind code of ref document: A2